310 related articles for article (PubMed ID: 18556158)
1. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers.
Yang W; Tam J; Miller DA; Zhou J; McConville JT; Johnston KP; Williams RO
Int J Pharm; 2008 Sep; 361(1-2):177-88. PubMed ID: 18556158
[TBL] [Abstract][Full Text] [Related]
2. Cryogenic liquids, nanoparticles, and microencapsulation.
Purvis T; Vaughn JM; Rogers TL; Chen X; Overhoff KA; Sinswat P; Hu J; McConville JT; Johnston KP; Williams RO
Int J Pharm; 2006 Oct; 324(1):43-50. PubMed ID: 16814968
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats.
Yang W; Johnston KP; Williams RO
Eur J Pharm Biopharm; 2010 May; 75(1):33-41. PubMed ID: 20102737
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution.
Yang W; Chow KT; Lang B; Wiederhold NP; Johnston KP; Williams RO
Eur J Pharm Sci; 2010 Mar; 39(5):336-47. PubMed ID: 20093186
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
[TBL] [Abstract][Full Text] [Related]
6. Stabilizer choice for rapid dissolving high potency itraconazole particles formed by evaporative precipitation into aqueous solution.
Sinswat P; Gao X; Yacaman MJ; Williams RO; Johnston KP
Int J Pharm; 2005 Sep; 302(1-2):113-24. PubMed ID: 16109466
[TBL] [Abstract][Full Text] [Related]
7. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole.
DiNunzio JC; Miller DA; Yang W; McGinity JW; Williams RO
Mol Pharm; 2008; 5(6):968-80. PubMed ID: 19434851
[TBL] [Abstract][Full Text] [Related]
8. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
9. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
Mou D; Chen H; Wan J; Xu H; Yang X
Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
[TBL] [Abstract][Full Text] [Related]
10. Single dose and multiple dose studies of itraconazole nanoparticles.
Vaughn JM; McConville JT; Burgess D; Peters JI; Johnston KP; Talbert RL; Williams RO
Eur J Pharm Biopharm; 2006 Jun; 63(2):95-102. PubMed ID: 16516450
[TBL] [Abstract][Full Text] [Related]
11. Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing.
Overhoff KA; Moreno A; Miller DA; Johnston KP; Williams RO
Int J Pharm; 2007 May; 336(1):122-32. PubMed ID: 17184938
[TBL] [Abstract][Full Text] [Related]
12. Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs.
Yin X; Daintree LS; Ding S; Ledger DM; Wang B; Zhao W; Qi J; Wu W; Han J
Drug Des Devel Ther; 2015; 9():2801-10. PubMed ID: 26060397
[TBL] [Abstract][Full Text] [Related]
13. Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability.
Miller MA; DiNunzio J; Matteucci ME; Ludher BS; Williams RO; Johnston KP
Drug Dev Ind Pharm; 2012 May; 38(5):557-70. PubMed ID: 21961961
[TBL] [Abstract][Full Text] [Related]
14. Fast-dissolving microparticles fail to show improved oral bioavailability.
Wong SM; Kellaway IW; Murdan S
J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
[TBL] [Abstract][Full Text] [Related]
15. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model.
McConville JT; Overhoff KA; Sinswat P; Vaughn JM; Frei BL; Burgess DS; Talbert RL; Peters JI; Johnston KP; Williams RO
Pharm Res; 2006 May; 23(5):901-11. PubMed ID: 16715380
[TBL] [Abstract][Full Text] [Related]
16. Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods.
Sim T; Lim C; Lee JW; Kim DW; Kim Y; Kim M; Choi S; Choi HG; Lee ES; Kim KS; Kang W; Oh KT
J Pharm Pharmacol; 2017 Dec; 69(12):1707-1715. PubMed ID: 28872678
[TBL] [Abstract][Full Text] [Related]
17. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media.
Matteucci ME; Brettmann BK; Rogers TL; Elder EJ; Williams RO; Johnston KP
Mol Pharm; 2007; 4(5):782-93. PubMed ID: 17715989
[TBL] [Abstract][Full Text] [Related]
18. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
19. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution.
Tam JM; McConville JT; Williams RO; Johnston KP
J Pharm Sci; 2008 Nov; 97(11):4915-33. PubMed ID: 18351641
[TBL] [Abstract][Full Text] [Related]
20. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.
Sun W; Ni R; Zhang X; Li LC; Mao S
Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
